Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, November 2, 2026

Back to today

BMRN Earnings Review

BioMarin’s Q3 revenue rose 32% to $1.02 billion after the Amicus acquisition, while lower 2026 guidance and $2.8 billion of net debt weighed on earnings.

BMRN $11B
Cestrian Capital Research 1 click

From X

@convequity 15 clicks

Convequity on X

We think the gross margin gap between Cerebras ($CBRS) and NVIDIA ($NVDA) says little about which company delivers compute more cheaply. Cerebras reported a 14% gross margin in Q2 2026, against roughly 75% for NVIDIA. That is not a clean comparison, because Cerebras's commercial agreements include customer warrants. A customer warrant gives a buyer of Cerebras compute the right to buy Cerebras shares at an agreed price, adding potential equity upside to the compute it purchases. Cerebras records the value of these incentives over time as a reduction in revenue. Its cost of delivering the compute stays the same, so the full amount comes out of gross profit and its reported gross margin falls too. Add the warrants and a few other items back and Cerebras's Q2 margin was 41%, so the reported gap tells us little about what each company spends to deliver equivalent compute. Cerebras could challenge NVIDIA with attractive economics on selected workloads without matching every capability of NVIDIA's platform. In our view NVIDIA's stronger answer is Feynman reaching customers on schedule with the 3D-stacked SRAM we expect. Stacking more fast memory close to the compute would reduce the need to fetch data from slower external memory, helping NVIDIA narrow the architectural advantage behind Cerebras's fast inference. NVIDIA's adoption of Groq technology could ease some of this pressure, but we believe Groq's current architecture remains weaker than Cerebras's for low-latency inference. The longer Feynman takes to arrive at scale, the more time Cerebras has to win customers.
@convequity 8 clicks

Convequity on X

We see Nova ($NVMI) as a potential next-generation KLA ($KLAC), and we are backing it to take a larger share of semiconductor process-control spending. Its wins with leading chipmakers are strengthening that case. A leading global foundry has selected Nova’s materials-measurement tools for production of its next generation of transistors. Another chipmaker has adopted a different Nova platform for the same transition. These wins show Nova securing a place in the manufacturing processes behind more advanced chips. KLA’s broader process-control business has a strong emphasis on finding and analysing manufacturing defects. Nova is more concentrated on measuring chip dimensions, material composition and the chemistry used in production. KLA also competes in these areas, but they are more central to Nova’s business. These measurements help manufacturers understand whether each production step is delivering the intended result and where adjustments are needed. As logic chips and memory stacks become more complex, manufacturers need tighter control over the structures they build and the materials they use. Small variations can hurt performance or reduce the number of usable chips. We expect this to increase demand for Nova’s measurements and create more opportunities for its tools to become essential to production. In our view, the Western semiconductor supply chain badly needs new entrants. Equipment leaders $AMAT, $KLAC, $LRCX and Tokyo Electron, design-software vendors $SNPS, $CDNS and Siemens, and $TSM in manufacturing are too cautious and slow to match the pace of startups and highly driven Chinese challengers. Protecting existing products and the returns on past investments can make these incumbents reluctant to pursue technologies that threaten their established businesses.

Investor Letters

All letters

Altria: Dutiful

Altria raised 2026 adjusted EPS guidance to $5.66 to $5.74 and authorized more buybacks, while on! loses share as cigarette margins hold.

MO $130B
Invariant 2 clicks
BR · long

Broadridge Financial Solutns

Broadridge Financial Solutions is framed as a high and rising free-cash-flow generator at a depressed valuation, with insider buying…

BR $21B
Value Investors Club

FTAI 3Q26: Aero margins in focus

FTAI’s Aerospace Products margin rebounded to 31% as CFM56 module output rose, while Power deposits and contracted deliveries fund its 2027…

FTAI $20B
Stock Thoughts 4 clicks

CVX Earnings Review

Chevron’s Q3 revenue rose 35% to $65.2 billion and EBITDA 75% to $20.2 billion, while production trailed guidance and refining margins…

CVX $423B
Cestrian Capital Research 3 clicks

SNY Earnings Review

Sanofi raised FY26 guidance after Q3 sales grew 14.3% at constant currency, led by 34.8% Dupixent growth; vaccines declined 6.6%.

SNY $114B
Cestrian Capital Research 1 click

TSOH Weekly Roundup (10/30/2026)

Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.

MKL $23B
TSOH Investment Research 1 click

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 73 of 273

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

297 firms

Sectors

Ordered by how often our editor reaches for them.